SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QCOR Questcor Pharmaceutical

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant12/29/2011 10:11:16 AM
  Read Replies (1) of 107
 
Questcor Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare
Conference on January 12, 2012

ANAHEIM, Calif., Dec. 29, 2011 /PRNewswire via COMTEX/ -- Questcor
Pharmaceuticals, Inc. (QCOR) announced today that executive management will
present at the 30th Annual J.P. Morgan Healthcare Conference on January 12, 2012
to be held on January 9-12, 2012 in San Francisco. Don M. Bailey, President and
Chief Executive Officer, is scheduled to present an overview of the Company on
Thursday, January 12, 2012 at 10:00 a.m. ET.

A live webcast and subsequent archived replay of the presentation will be
accessible at ir.questcor.com. The replay will be available for
90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary
product, Acthar, helps patients with serious, difficult-to-treat medical
conditions. Questcor's primary product is H.P. Acthar? Gel (repository
corticotropin injection), an injectable drug that is approved by the FDA for the
treatment of 19 indications. Of these 19 indications, Questcor currently
generates substantially all of its net sales from three indications: the
treatment of acute exacerbations of multiple sclerosis in adults, the treatment
of nephrotic syndrome, and the treatment of infantile spasms in children under
two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar
to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome
without uremia of the idiopathic type or that due to lupus erythematosus."
Questcor is also exploring the use of Acthar to treat systemic lupus
erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy
and to treat exacerbations. Questcor is also exploring the possibility of
developing markets for other on-label indications and the possibility of pursuing
FDA approval of additional indications not currently on the Acthar label where
there is high unmet medical need. In October 2011, Forbes magazine ranked
Questcor number one in its annual rankings of America's Best Small Companies. For
more information, please visit questcor.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext